Rhythm

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Food and Drug Administration (FDA) has cleared BioCardia to market the Morph DNA Steerable Introducer product family, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act.

AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently […]

PaceMate® Acquires Medtronic Paceart Optima™ System, Bringing Complementary Capabilities to Cardiac Data Management

August 27, 2024 08:00 AM Eastern Daylight Time SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE: MDT.) This strategic move significantly expands […]

Biosense Webster Completes Enrollment of Omny-IRE Clinical Trial Investigating the OMNYPULSE™ Large-tip Focal Pulsed Field Ablation Catheter

Study evaluates the safety and effectiveness of the OMNYPULSE™ Platform in Europe and Canada Irvine, CA – August 26, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced the enrollment completion […]

Leading Cardiac Diagnostics Innovator Zywie Announces Industry Partnership With MedAxiom

ATLANTA–(BUSINESS WIRE)–Zywie, a cardiovascular diagnostics pioneer specializing in remote cardiac monitoring through wearable biosensor devices and cloud-based data analytic solutions, announced today a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions. “We are proud to welcome Zywie to the MedAxiom community” […]

Atraverse Medical Announces First Clinical Use of HOTWIRE™ Radiofrequency (RF) Guidewire System at St. Bernards Medical Center

SAN DIEGO, July 30, 2024 /PRNewswire/ — The HOTWIRE™ RF guidewire device by Atraverse Medical, a San Diego-based medical device company, has been used for the first time in clinical practice by world-renowned cardiac electrophysiologist, Dr. Devi Nair, at St. Bernards Medical Center. The…

Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled “Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency” focused on the MyoVista® wavECG™’s potential to radically improve the cardiovascular pathway efficiency.